Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2007-04-10
2007-04-10
Chen, Stacy B. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S211100, C435S069100, C536S023720
Reexamination Certificate
active
09586479
ABSTRACT:
Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an anti-PIV immune response or as vectors for introducing heterologous genes into a host. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete “background” PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different PIV virus to form the human-bovine chimeric PIV genome or antigenome.
REFERENCES:
patent: 5716821 (1998-02-01), Wertz et al.
patent: 5789229 (1998-08-01), Wertz et al.
patent: 5869036 (1999-02-01), Belshe et al.
patent: 6033886 (2000-03-01), Conzelmann
patent: 6264957 (2001-07-01), Collins
patent: 0 440 219 (1991-08-01), None
patent: 0 702 085 (1996-03-01), None
patent: WO 92/01471 (1992-02-01), None
patent: WO 93/14207 (1993-07-01), None
patent: WO 93/21310 (1993-10-01), None
patent: WO 97/06270 (1997-02-01), None
patent: WO 97/11093 (1997-03-01), None
patent: WO 97/12032 (1997-04-01), None
patent: WO 97/20468 (1997-06-01), None
patent: WO 98/02530 (1998-01-01), None
patent: WO 98/43668 (1998-10-01), None
patent: WO 98/53078 (1998-11-01), None
patent: WO 99/02657 (1999-01-01), None
patent: WO 99/15631 (1999-04-01), None
patent: WO 99/24564 (1999-05-01), None
patent: WO 00/61611 (2000-10-01), None
patent: WO 00/61737 (2000-10-01), None
patent: WO 01/04271 (2001-01-01), None
patent: WO 01/04321 (2001-01-01), None
patent: WO 01/04335 (2001-01-01), None
Bailly et al., “A Recombinant Human Parainfluenza Virus Type 3 (PIV3) in Which the Nucleocapsid N Protein Has Been Replaced by That of Bovine PIV3 Is Attenuated in Primates,”J. Virol.74(7):3188-3195, 2000.
Baron et al., “Rescue of Rinderpest Virus from Cloned cDNA,”J. Virol.71:1265-1271, 1997.
Bellini et al., “Measles VirusPGene Codes for Two Proteins,”J. Virol.53:908-19, 1985.
Belshe et al., “Cold Adaptation of Parainfluenza Virus Type 3: Induction of Three Phenotypic Markers,”J. Med. Virol.10:235-42, 1982.
Blumberg et al., “Measles Virus L Protein Evidences Elements of Ancestral RNA Polymerase,”Virology164:487-497, 1988.
Buchholz et al., “Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture, and the Human RSV Leader Region Acts as a Functional BRSV Genome Promoter,”J. Virol.73:251-259, 1999.
Buchholz et al., “Chimeric Bovine Respiratory Syncytial Virus with Glycoprotein Gene Substitutions from human Respriatory Syncytial Virus (HRSV): Effects on Host Range and Evaluation as a Live-Attenuated HRSV Vaccine,”J. Virol.74:1187-1199, 2000.
Bukreyev, et al., “Recovery of Infectious Respiratory Syncytial Virus Expressing an Additional, Foreign Gene,”J. Virol.70:6634-41, 1996.
Bukreyev, et al., “Recombinant Respiratory Syncytial virus from which the Entire SH Gene has been Deleted Grows Efficiently in Cell Culture and Exhibits Site-Specific Attenuation in the Respiratory Tract of the Mouse,”J. Virol.71:8973-8982, 1997.
Bukreyev, et al., “Interferon γ Expressed by a Recombinant Respiratory Syncytial Virus Attenuates Virus Replication in Mice Without Compromising Immunogenicity,”Proc. Nat. Acad. Sci. USA96:2367-2372, 1999.
Cadd et al., “The Sendai Paramyxiovirus Accessory C Proteins Inhibit Viral Genome Amplification in Promoter-Specific Fashion,”J. Virol.70:5067-74, 1996.
Cattaneo et al., “Measles Virus Editing Provides an Additional Cysteine-Rich Protein,”Cell56:759-764, 1989.
Clememts et al.,J. Clin. Mirobiol.27:219-222, 1989.
Clements et al.,J. Clin. Microbiol.30:655-662, 1992.
Clements-Mann et al.,Vaccine17:2715-2725, 1999.
Collins et al., “Rescue if Synthetic Analogs of Respiratory Syncytial Virus Genomic RNA and Effect of Truncations and Mutations on the Expression of a Foreign Reporter Gene,”Proc. Natl. Acad. Sci. USA, 88:9663-9667, 1991.
Collins, et al., “Rescue of a 7502-Nucleotide (49.3% of Full-Length) Synthetic Analog of Respiratory Syncytial Virus Genomic RNA,”Virology195:252-256, 1993.
Collins, et al., “Production of Infectious Human Respiratory Syncytial Virus from Cloned cDNA Confirms an Essential Role of the Transcription Elongation Factor from the 5′ Proximal Open Reading Frame of the M2 mRNA in Gene Expression and Provides a Capability for Vaccine Development,”Proc. Nat. Acad. Sci. USA92:11563-11567, 1995.
Collins et al., “Parainfluenza Viruses”, inFields Virology, B. N. Fields (Knipe et al., eds.), 3rded., vol. 1, p. 1205-1243, Lippincott-Raven Publishers, Philadelphia, 1996.
Connors et al., “A Cold-Passaged, Attenuated Strain of Human Resporatory Syncytial Virus Contains Mutations in the F and L Genes,”Virology208:478-484, 1995.
Conzelmann et al., “Rescue of Synthetic Genomic RNA Analogs of Rabies Virus by Plasmid-Encoded Proteins,”J. Virol.68:713-719, 1994.
Conzelmann, “Genetic Manipulation of Non-Segmented Negative-strand RNA Viruses,”J. Gen. Virol.77:381-389, 1996.
Crowe, et al., “A Further Attenuated Derivative of a Cold-Passaged Temperature-Sensitive Mutant of Human Respiratory Syncytial Virus Retains Immunogenicity and Protective Efficacy Against Wild-Type Challenge in Seronegative Chimpanzees,”Vaccine12:783-790, 1994.
Crowe, et al., “Acquisition of thetsPhenotype by a Chemically Mutagenized Cold-Passaged Human Respiratory Syncytial Virus Vaccine Candidate Results from the Acquisition of a Single Mutation in the Polymerase (L) Gene,”Virus Genes13:269-273, 1996.
Curran, et al., “Sendai Virus P Gene Produces Multiple Proteins from Overlapping Open Reading Frames,”Enzyme44:244-249, 1990.
Curran, et al., “The Sendai Virus Nonstructural C Proteins Specifically Inhibit Viral mRNA Synthesis,”Virology189:647-656, 1992.
Delenda, et al., “Normal Cellular Replication of Sendai Virus Without thetrans-Frame, Nonstructural V Protein,”Virology228:55-62, 1997.
Delenda et al., “Sendai Viruses with Altered P, V, and W Protein Expression,”Virology242:327-337, 1998.
Dimock, et al., “Rescue of Synthetic Analogs of Genomic RNA and Replicative-Intermediate RNA of Human Parainfluenza Virus Type 3,”J. Virol.67: 2772-2778, 1993.
Durbin et al., “Minimum Protein Requirements for Transcription and RNA Replication of a Minigenome of Human Parainfluenza Virus Type 3 and Evaluation of the Rule of Six,”Virology234:74-83, 1997.
Durbin et al., “Recovery of Infectious Human Parainfluenza Virus Type 3 from cDNA,”Virology235:323-332, 1997.
Durbin et al., “Mutations in the C, D, and V Open Reading Frames of Human Parainfluenza Virus Type 3 Attenuate Replication in Rodents and Primates,” Virology 6l 261:319-330, 1999—yes.
Escoffier et al., “Nonstructural C Protein is Required for Efficient Measles Virus Replication in Human Peripheral Blood Cells,”J. Virol.73:1695-8, 1999.
Firestone et al., “Nucleotide Sequence Analysis of the Respiratory Syncytial Virus Subgroup A Cold-Passaged (cp) Temperature Sensitive (ts)cpts-248/404 Live Attenuated Virus Vaccine Candidate,”Virology225:419-422, 1996.
Galinski et al., “Molecular Cloning and Sequence Analysis of the Human Parainfluenza 3 Virus mRNA Encoding the P and C Proteins,”Virology155:46-60, 1986.
Galinski et al., “Molecular Cloning and Sequence Analysis of the Human Parainfluenza 3 Virus Gene Encoding the L Prot
Bailly Jane E.
Collins Peter L.
Durbin Anna P.
Murphy Brian R.
Schmidt Alexander C.
Birch & Stewart Kolasch & Birch, LLP
Chen Stacy B.
The United States of America, Represented by the Secretary, Depa
LandOfFree
Attenuated human-bovine chimeric parainfluenza virus(PIV)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Attenuated human-bovine chimeric parainfluenza virus(PIV)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuated human-bovine chimeric parainfluenza virus(PIV)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3755027